A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
AstraZeneca
Study ID
NCT07667803
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Weight Management

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Elecoglipron — DRUG
    Elecoglipron film-coated tablet once daily
  • Placebo — DRUG
    Placebo matching elecoglipron film-coated tablet once daily

Study Details

This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).

Key Dates

First listed
Jun 25, 2026
Start date
Jun 29, 2026
Status verified
Jul 2026
Primary completion
Jul 31, 2028
Completion
Jul 30, 2029

Study Design

Enrollment
4,500 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm 1 - Dose 1
    Active IMP
  • Experimental: Arm 2 - Dose 2
    Active IMP
  • Placebo Comparator: Arm 3 - Placebo
    Placebo matching elecoglipron

Primary Outcome Measure

Percent body weight loss [ Time Frame: 72 weeks ]

Central Contacts

Locations (56)

FacilityCityStateZIPSite coordinators
Research SiteBirminghamAlabama35205-
Research SiteDothanAlabama36305-
Research SiteChandlerArizona85225-
Research SitePeoriaArizona85382-
Research SiteLittle RockArkansas72205-
Research SiteLynwoodCalifornia90262-
Research SiteRolling Hills EstatesCalifornia90274-
Research SiteSacramentoCalifornia95821-
Research SiteArvadaColorado80002-
Research SiteNew HavenConnecticut06511-
Research SiteClearwaterFlorida33765-
Research SitePlantationFlorida33324-
Research SiteWoodstockGeorgia30189-
Research SiteAmmonIdaho83406-
Research SiteMelrose ParkIllinois60160-
Research SiteIndianapolisIndiana46254-
Research SiteWichitaKansas67218-
Research SiteLouisvilleKentucky40213-
Research SiteAlexandriaLouisiana71303-
Research SiteBaltimoreMaryland21229-
Research SitePotomacMaryland20854-
Research SiteWhite MarshMaryland21162-
Research SiteYpsilantiMichigan48197-
Research SiteRidgelandMississippi39157-
Research SiteKansas CityMissouri64114-
Research SiteSt LouisMissouri63123-
Research SiteRenoNevada89511-
Research SiteAlbuquerqueNew Mexico87106-
Research SiteAlbanyNew York12205-
Research SiteLaureltonNew York11413-
Research SiteLong Island CityNew York11106-
Research SiteGreensboroNorth Carolina27408-
Research SiteRaleighNorth Carolina27609-
Research SiteRocky MountNorth Carolina27804-
Research SiteStatesvilleNorth Carolina28625-
Research SiteColumbusOhio43228-
Research SiteDaytonOhio45424-
Research SiteEdmondOklahoma73013-
Research SiteTulsaOklahoma74133-
Research SitePortlandOregon97223-
Research SiteDuBoisPennsylvania15801-
Research SiteNewportPennsylvania17074-
Research SitePhiladelphiaPennsylvania19104-
Research SiteEast ProvidenceRhode Island02914-
Research SiteCharlestonSouth Carolina29407-
Research SiteGaffneySouth Carolina29340-
Research SiteRapid CitySouth Dakota57701-
Research SiteFranklinTennessee37067-
Research SiteKnoxvilleTennessee37912-
Research SiteDallasTexas75254-
Research SiteHoustonTexas77081-
Research SiteHumbleTexas77346-
Research SiteIrvingTexas75063-
Research SiteSandy CityUtah84070-
Research SiteMidlothianVirginia23112-
Research SiteMorgantownWest Virginia26501-

Related Studies